Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Insights - The report highlights that the domestic policy environment is continuously releasing positive signals, with the 2026 government work report explicitly listing biomedicine as a "new pillar industry" [6][7] - The report indicates that the pharmaceutical and biotechnology industry index declined by 2.99%, underperforming the CSI 300 index, with medical consumables and in vitro diagnostics showing positive growth [5][15] - The report emphasizes the importance of focusing on "independent innovation" and "policy benefits" as the main investment themes in the pharmaceutical and biotechnology sector [7] Industry Review - The pharmaceutical and biotechnology industry index experienced a decline of 2.99%, ranking 14th among 31 primary industries, and underperformed the CSI 300 index, which declined by 0.88% [5][15] - Medical consumables and in vitro diagnostics had the highest growth rates of 1.42% and 0.93%, respectively, while medical devices and medical research outsourcing saw declines of 6.57% and 6.54% [5][15] - As of March 13, 2026, the industry’s PE (TTM overall method, excluding negative values) was 30.34x, down from 31.06x, indicating a downward trend in valuation [20] Important Industry News - The 2026 government work report has been released, emphasizing biomedicine as a "new pillar industry" and proposing to expand pilot programs in biotechnology and accelerate the development of innovative drugs and medical devices [25][26] - The "14th Five-Year Plan" has been published, mentioning the pharmaceutical industry multiple times, reinforcing support for innovative drugs and related sectors [25][26] - Notable approvals include the global first cAMP biased GLP-1 receptor agonist "Elnoglutide Injection" by Hangzhou Xianweida Biotech and a $30 billion investment by Eli Lilly in China [6][34][43] Investment Recommendations - The report suggests focusing on high-quality pharmaceutical assets with differentiated innovation capabilities and sustainable potential, particularly those benefiting from policy support and high-quality development of innovative drugs [7] - The investment themes should concentrate on companies with strong clinical advancement capabilities and global cooperation potential, as well as those benefiting from the optimization of review and approval processes and payment systems [7]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Insights - The report highlights that the domestic policy environment is continuously releasing positive signals, with the 2026 government work report explicitly listing biomedicine as a "new pillar industry" [6][25] - The report indicates that the pharmaceutical and biotechnology industry index declined by 2.99%, underperforming the CSI 300 index, with medical consumables and in vitro diagnostics showing positive growth [5][15] - The report emphasizes the importance of focusing on "independent innovation" and "policy benefits" as the main investment themes in the pharmaceutical and biotechnology sector [7] Industry Review - The pharmaceutical and biotechnology industry index experienced a decline of 2.99%, ranking 14th among 31 primary industries, and underperformed the CSI 300 index, which declined by 0.88% [5][15] - The valuation of the pharmaceutical and biotechnology industry as of March 13, 2026, is 30.34x (TTM overall method, excluding negative values), down from 31.06x in the previous period, indicating a downward trend [20] - Among the sub-industries, the top three in terms of PE (TTM overall method, excluding negative values) are vaccines (54.84x), hospitals (41.28x), and medical consumables (39.52x), while the lowest is pharmaceutical circulation (14.66x) [20] Important Industry News - The 2026 government work report has been released, emphasizing biomedicine as a "new pillar industry" and proposing to further expand pilot programs in biotechnology and accelerate the development of innovative drugs and medical devices [6][25] - The "14th Five-Year Plan" outlines multiple references to the pharmaceutical industry, reinforcing support for innovative drugs and related sectors [25][26] - Notable approvals include the global first cAMP biased GLP-1 receptor agonist "Elnoglutide Injection" by Hangzhou Xianweida Biotech and a $30 billion investment by Eli Lilly in China [6][33][42] Investment Recommendations - The report suggests focusing on high-quality pharmaceutical assets with differentiated innovation capabilities and sustainable potential, particularly those benefiting from the high-quality development of innovative drugs and supportive policies [7] - It is recommended to pay attention to innovative drug companies with strong clinical advancement capabilities and global cooperation potential, as their valuation systems are expected to upgrade from single product logic to platform logic [7]

Market Overview - The three major A-share indices collectively declined, with the Shanghai Composite Index falling below the 4100-point mark, indicating a weakening short-term moving average system [5] - A total of 1743 stocks rose, with a significant improvement in the up-down limit ratio to 46:27, although the overall profit-making effect remains poor [5] Sector Performance - The sectors showing the most gains included power grid equipment, agriculture, and military equipment, while gas, port shipping, and precious metals sectors experienced declines [5] Capital Flow - There was a net outflow of main funds amounting to billions, with total market turnover decreasing by 24.40% [5] - Institutional investors are adopting a strategy of "shrinking positions, optimizing structure, and buying on dips," significantly reducing exposure to high-risk sectors like oil and gas, shipping, and precious metals, while increasing allocations to low-risk sectors such as power grid equipment, military, and agriculture [7] Retail Investor Behavior - Retail investors are showing a cautious approach, characterized by "careful bottom-fishing and positioning in oversold stocks," avoiding high-risk sectors and instead focusing on AI, semiconductors, and new energy sectors that have undergone sufficient adjustments [7] - Retail investor sentiment stands at 75.85%, indicating a generally cautious outlook [8] Trading Sentiment - 30.53% of investors are increasing their positions, while 16.03% are reducing their holdings, with a significant portion choosing to remain inactive [11] - The sentiment regarding the next trading day is split, with 54.73% expecting a decline and 45.27% anticipating an increase [14]

Group 1 - The A-share market continues to show strong upward momentum, with the Shanghai Composite Index achieving an eight-day winning streak, closing up 0.48% at 3683.46 points, the highest since December 2021 [1][2] - The trading volume significantly increased, with a total turnover of 2.18 trillion yuan, marking the second-highest record of the year, indicating heightened trading activity and increased willingness of external funds to enter the market [1][2] - The market's upward trend is supported by policy incentives and an improved external environment, including the extension of US-China tariff negotiations and rising expectations for Federal Reserve interest rate cuts, which alleviated previous uncertainties [1][5] Group 2 - The A-share market displayed structural trends, with sectors such as telecommunications (+4.91%), non-ferrous metals (+2.37%), electronics (+2.01%), and pharmaceuticals (+1.73%) leading the gains, while over a hundred stocks hit the daily limit up [2] - The Hong Kong stock market also experienced a strong rally, with the Hang Seng Index rising 2.58% and the Hang Seng Technology Index increasing by 3.52%, marking the largest gain in three months [3] - Key sectors driving the market include technology and healthcare, with significant increases in indices related to medical care and innovative drugs [3] Group 3 - The telecommunications sector is experiencing a surge, driven by the demand for computing power infrastructure, with companies in this space reporting substantial profit increases, some exceeding 300% [4] - The non-ferrous metals sector, particularly the copper industry, is performing strongly, supported by rising prices in the storage market and an overall improvement in electronic materials [4] - The pharmaceutical sector is stabilizing due to supportive policies for innovative drugs, while high-end manufacturing sectors like robotics and power equipment are seeing a return of funds [4] Group 4 - The market is characterized by an influx of incremental funds, with continuous increases in trading volume and margin financing balances, alongside supportive policies for personal and service industry loans [5] - Short-term strategies should focus on sectors with significant trading volume and trend breakthroughs, such as AI hardware and brokerage firms, while avoiding traditional cyclical stocks under pressure [5] - Mid-term investment should target three main lines: the broad technology sector, new consumption driven by policy incentives, and non-ferrous metals driven by industrial upgrades and new energy demands [5]